Dr. Kris on the Crizotinib Clinical Trials

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the goal in cancer care has been to know enough about cancer to find a characteristic that is a weakness to the cancer and exploit it.

When discussing the clinical trial Kris explains that only patients with an EML4-ALK translocation were allowed into the crizotinib clinical trial. He compares crizotinib to imatinib in BCR-ABL patients.